Deciphering the Precise Role of Complement Activation in IgA Nephropathy to Develop Therapeutic Inhibitors

Time: 11:45 am
day: Pre-Conference Seminar Day


  • Discussing the role of the complement cascade in the pathogenesis of IgA nephropathy
  • Review results of the Phase II trial of RO7434656, an antisense oligonucleotide targeting complement
  • Providing an overview of the Phase III IMAgINATION trial of RO7434656 in patients with IgA nephropathy